PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia.

doi:10.1016/j.biopha.2023.115066

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Sept 2023

Choi Yong June, Park Jaewoo, Choi Hyoyi, Oh Su-Jin, Park Jin-Hee, Park Miso, Kim Ji Won, Kim Yoon-Gyoon, Kim Yong-Chul, Kim Myung Jin, Kang Keon Wook

Abstract excerpt

Acute myeloid leukemia (AML) is a prevalent form of leukemia in adults. As its survival rate is low, there is an urgent need for new therapeutic options. In AML, FMS-like tyrosine kinase 3 (FLT3) mutations are common and have negative outcomes. However, current FLT3-targeting agents, Midostaurin...

Topics

Adult
Humans
fms-Like Tyrosine Kinase 3
Leukemia, Myeloid, Acute
Protein Kinase Inhibitors
Mutation
Proto-Oncogene Proteins c-ret

Source

Open in PubMed

Identifiers

PMID: 37392657
DOI: 10.1016/j.biopha.2023.115066

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-37392657-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics